The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Effect of p53 Status on Tumor Response to Antiangiogenic Therapy
Abstract
The p53 tumor suppressor gene is inactivated in the majority of human cancers. Tumor cells deficient in p53 display a diminished rate of apoptosis under hypoxic conditions, a circumstance that might reduce their reliance on vascular supply, and hence their responsiveness to antiangiogenic therapy. Here, we report that mice bearing tumors derived from p53 −/− HCT116 human colorectal cancer cells were less responsive to antiangiogenic combination therapy than mice bearing isogenic p53 +/+ tumors. Thus, although antiangiogenic therapy targets genetically stable endothelial cells in the tumor vasculature, genetic alterations that decrease the vascular dependence of tumor cells can influence the therapeutic response of tumors to this therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Self-citationInterferon Alfa-2a Therapy for Life-Threatening Hemangiomas of Infancy
Ezekowitz, R. A. B., Mulliken, J. B., & Folkman, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205283262203 · Cited by 1,071
Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression
Semenza, G. L. (2000) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230091169186 · Cited by 654
Combination bacteriolytic therapy for the treatment of experimental tumors
Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W., & Vogelstein, B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251543698 · Cited by 563
Kerbel, R. S. (1991) · BioEssays · doi:10.1002/bies.950130106 · Cited by 441
Self-citationAnti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.
Chaplin, D. J., Pettit, G. R., & Hill, S. A. (1999) · PubMed · Cited by 252
Antiangiogenic Therapy of a Recurrent Giant Cell Tumor of the Mandible With Interferon Alfa-2a
Kaban, L. B., Mulliken, J. B., Ezekowitz, R. A., Phil, D., Ebb, D., Smith, P. S., & Folkman, J. (1999) · Pediatrics · doi:10.1542/peds.103.6.1145 · Cited by 245
Kerbel, R. S., Yu, J., Tran, J., Man, S., Viloria-Petit, A., Klement, G., Coomber, B. L., & Rak, J. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1013172910858 · Cited by 237
Self-citationDetection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts.
Lord, E. M., Harwell, L. W., & Koch, C. J. (1993) · PubMed · Cited by 223
Targeting tumour vasculature: the development of combretastatin A4
Griggs, J., Metcalfe, J. C., & Hesketh, R. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00224-2 · Cited by 207
Rak, J., Filmus, J., & Kerbel, R. S. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00396-6 · Cited by 202
Self-citationCancer: looking outside the genome
Folkman, J., Hahnfeldt, P., & Hlatky, L. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35036100 · Cited by 193
Heterogeneous Vascular Dependence of Tumor Cell Populations
Yu, J., Rak, J. W., Carmeliet, P., Nagy, A., Kerbel, R. S., & Coomber, B. L. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64083-7 · Cited by 150
Self-citationTirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia
Denny, W. A., & Wilson, W. R. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.12.2889 · Cited by 104
Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (Review)
Blagosklonny, M. V. (2001) · International Journal of Oncology · doi:10.3892/ijo.19.2.257 · Cited by 92
Treating cancer by inhibiting angiogenesis: new hopes and potential pitfall
Rak, J. W., & Kerbel, R. S. (1996) · Cancer and Metastasis Reviews · doi:10.1007/bf00437476 · Cited by 71
Self-citationHypoxic cytotoxic agents: a new approach to cancer chemotherapy
Brown, J. M. (2000) · Drug Resistance Updates · doi:10.1054/drup.2000.0120 · Cited by 21
(1995) · PubMed
Cited by
Dissemination and growth of cancer cells in metastatic sites
Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc865 · Cited by 3,911
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Self-citation
Metadata
- Authors
- Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S.
- Venue
- Science
- Published
- 2002-02-22
- Volume
- 295
- Issue
- 5559
- Pages
- 1526-1528
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2080237506
- Cited by
- 426
- References
- 23
- FWCI
- 15.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.